Tech Company Financing Transactions
Oligomerix Funding Round
Oligomerix, based in Bronx, secured $2 million from Durand Venture Associates, Wheatley Partners and private investors.
Transaction Overview
Company Name
Announced On
4/24/2012
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Series A
Investors
Durand Venture Associates (Lead Investor)
Wheatley Partners (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to advance Oligomerix's tau protease inhibitor program, which aims to neutralize tau outside of neurons, offering a more feasible approach to drug discovery than targeting intraneuronal tau oligomer formation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1300 Morris Park Ave. 1211
Bronx, NY 10461
USA
Bronx, NY 10461
USA
Phone
Website
Email Address
Overview
OLIGOMERIX Inc., is a biopharmaceutical company focused on developing novel drug discovery targets and therapeutics for Alzheimer's disease and other neurodegenerative disorders. Founded in 2006, OLIGOMERIX has filed patents on tau protein oligomers (soluble aggregates) for drug and biomarker discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Moe
Chief Financial Officer
Robert Foerster
Chief Medical Officer
William Erhardt
Chief Scientific Officer
Eliot Davidowitz
VP - Marketing
Jack Pasini
Browse more venture capital transactions:
Prev: 4/24/2012: Parking Panda venture capital transaction
Next: 4/24/2012: EnerTrac venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs